Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018

TARRYTOWN, N.Y., Jan. 23, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it will report its fourth quarter and full year 2017 financial and operating results onThursday, February 8, 2018, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at8:30 AM Eastern Timethat day.

Conference Call InformationTo access this call, dial (800) 708-4539 (U.S.) or (847) 619-6396 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website atwww.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

About RegeneronRegeneron (NASDAQ:REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, Regeneron's unique ability to consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates, all of which were homegrown in its laboratories. Regeneron's medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietaryVelociSuite®technologies, including VelocImmune®to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visitwww.regeneron.comor follow @Regeneron on Twitter.